A 53-year-old Japanese man with multiple sclerosis developed autoimmune neutropenia. The neutrophil count was consistently less than 0.2xl09//, irrespective of the disease activity of multiple sclerosis or the administration of immunosuppressive agents or granulocyte colony-stimulating factor. After high-dose y-globulin therapy was started, temporary increases in the neutrophil count were observed. Despite a wide spectrum of clinical manifestations in multiple sclerosis, autoimmune neutropenia has never been reported previously. (Internal Medicine 42: 102-104, 2003) 
Introduction
Autoimmuneneutropenia (AIN) is a disorder caused by increased peripheral destruction of neutrophils as a result of antibodies in the patient's blood that are directed against their own neutrophils (1, 2). Acquired AIN has been associated with various disorders, including collagen vascular diseases (rheumatoid arthritis and Felty's syndrome, Sjogren's syndrome, and systemic lupus erythematosus), immune cytopenias (idiopathic thrombocytopenic purpura and Evans' syndrome) and lymphoproliferative disorders (large granular lymphocyte leukemia, malignant lymphoma) (3-7 (Fig. 1) . However, a high-dose y-globulin therapy (400 mg/kg daily intravenously for 4 days) resulted in a transient increase in neutrophil counts up to 3.7xl09//.
Discussion
He has not suffered from severe infections despite the long-standing and profound neutropenia. This could be partly associated with the administration of granulocyte colony-stimulating factor which actively enhances neutrophil functions (9). However, it has also been knownthat patients with acquired AINare often asymptomatic concerning infections and neutropenia is detected mostly by chance (2) . In addition to the demonstration of autoantibodies directed against the neutrophil-specific antigen FcyRIIIb, an absence of recurrent infections is consistent with the clinical diagnosis of acquired AIN. MSis a demyelinating disease of the central nervous system (CNS) (10) . Several reports have described the presence of autoantibodies recognizing myelin basic protein, myelin proteolipid protein, myelin-associated glycoprotein, myelin-oligodendrocyte glycoprotein and other CNS antigens (ll-13) . In the present case the repeated neurological exacerbations responded to immunosuppressive therapies including high-dose methylprednisolone therapy, lymphocytapheresis and oral cyclosporine treatment, while the neutropenia remained unchanged. Nevertheless, the neutrophil count increased in response to the intravenous yglobulin therapy. The efficacy of intravenous y-globulin therapy has been described in patients with both MS (14) and AIN (15) . The transitory neutrophil recovery may suggest that the mechanisms of action of intravenous y-globulin could mainly include blockade of reticuloendothelial system Fc receptors and interference in the binding of autoantibodies to target neutrophils. Because of the almost simultaneous manifestation of MS and AIN, the association of these two disorders does not seem to be coincidental. Although it is unclear whether the antibodies recognizing neutrophil antigens and CNSantigens had cross-reactivities, we speculate that the immunogenetic abnormalities underlying the pathology of MS might be closely associated with the development of AIN. Our experience suggests that AINcan occur as a hematologic presentation of MS.
